Table II.
Relationship between highly upregulated in liver cancer expression (HULC) levels and clinicopathological features of patients with breast cancer (n=52)
| Characteristics | Number of patients (%) | HULC mean (ΔCt)±SEM | P |
|---|---|---|---|
| Age (yr) | |||
| <45 | 24 (46.7) | 15.46±0.75 | 0.537 |
| >45 | 28 (53.3) | 14.86±0.63 | |
| Tumour size (cm) | |||
| <2 | 24 (46.2) | 14.22±0.69 | 0.182 |
| >2 | 20 (38.5) | 15.68±0.84 | |
| TNM clinical stage | |||
| I | 17 (32.7) | 17.10±0.66 | 0.025 |
| II | 14 (26.9) | 14.45±1.01 | |
| III | 14 (26.9) | 13.74±0.87 | |
| Lymphatic metastasis | |||
| Absent | 17 (32.7) | 15.80±0.61 | 0.052 |
| Present | 28 (53.8) | 13.66±0.94 | |
| Differentiation | |||
| Poor | 5 (9.6) | 12.56±1.46 | 0.284 |
| Moderate | 35 (67.3) | 15.26±0.58 | |
| Well | 5 (9.6) | 15.53±2.13 | |
| Progesterone expression (%) | |||
| <30 | 13 (38.2) | 14.91±1.21 | 0.914 |
| >30 | 21 (61.8) | 15.06±0.77 | |
| Oestrogen expression (%) | |||
| <30 | 17 (32.7) | 16.12±0.79 | 0.088 |
| >30 | 17 (32.7) | 13.89±0.99 | |
| HER-2 status | |||
| Negative | 16 (30.8) | 14.93±1.04 | 0.891 |
| Positive | 15 (28.8) | 15.13±0.98 | |
| Location | |||
| Right | 20 (38.5) | 14.81±0.84 | 0.549 |
| Left | 23 (44.2) | 15.45±0.68 |
HER-2, human epidermal growth factor receptor-2; TNM, tumour, node, and metastasis; SEM, standard error of mean